Odonate Therapeutics Inc
OTC:ODTC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22 005
176 040
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value of ODTC.
The Intrinsic Value is calculated as the average of DCF and Relative values:
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Odonate’s single-asset pipeline—centered on Tesetaxel—amplifies uncertainty, as any major setback in clinical trials or regulatory reviews could dramatically limit the company’s future prospects and valuation.
Limited commercialization infrastructure and dependence on licensing or partnership agreements increase Odonate’s expenditures while offering no guaranteed revenue source, eroding cash reserves without near-term top-line contributions.
Rival oncology therapies from larger, well-capitalized competitors pose a significant threat, reducing Odonate’s ability to capture market share, and potentially undermining the viability of Tesetaxel in the broader breast cancer treatment landscape.
If Tesetaxel gains approval and demonstrates meaningful clinical benefits over existing therapies, Odonate could capture a lucrative niche in the breast cancer market, driving substantial revenue growth.
Odonate’s lean operating model and focus on a singular high-potential therapy position it for efficient cost management, potentially enhancing returns if Tesetaxel successfully clears pivotal trials.
Positive clinical data and a clear regulatory path could attract partnership or acquisition interest from larger pharma companies, offering a significant upside for shareholders in both the near and long term.
Revenue & Expenses Breakdown
Odonate Therapeutics Inc
Balance Sheet Decomposition
Odonate Therapeutics Inc
| Current Assets | 99.6m |
| Cash & Short-Term Investments | 95m |
| Other Current Assets | 4.6m |
| Non-Current Assets | 6.2m |
| PP&E | 5.4m |
| Other Non-Current Assets | 768k |
| Current Liabilities | 30.3m |
| Accounts Payable | 11.7m |
| Accrued Liabilities | 18.6m |
| Non-Current Liabilities | 4.1m |
| Other Non-Current Liabilities | 4.1m |
Free Cash Flow Analysis
Odonate Therapeutics Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Odonate Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-90.7m
USD
|
|
Operating Income
|
-90.7m
USD
|
|
Other Expenses
|
-11.4m
USD
|
|
Net Income
|
-102.1m
USD
|
ODTC Profitability Score
Profitability Due Diligence
Odonate Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Odonate Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
ODTC Solvency Score
Solvency Due Diligence
Odonate Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Odonate Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ODTC Price Targets Summary
Odonate Therapeutics Inc
Dividends
Current shareholder yield for ODTC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?